PureRawz: FDA Warning Letter Record (September 8, 2025)

Updated September 6, 2026

FDA issued warning letter 715218 to PureRawz of Knoxville, Tennessee on September 8, 2025, after reviewing the firm's website in August 2025. Five products were cited, all of them tianeptine preparations. No peptide appears anywhere in the letter. That matters because FDA's own scientific reviewers had separately cited this same website — its TB-500 product page — as evidence of how TB-500 is marketed, in a briefing document prepared for the agency's Pharmacy Compounding Advisory Committee. The two documents came out of the same FDA office and have nothing to do with each other. This record exists to show what that does, and does not, prove.

Record at a glance

What the letter actually cites

The letter opens by recording what FDA looked at and when: the agency reviewed your website at the internet address https://purerawz.co in August 2025, along with the firm's Facebook and Instagram accounts. It notes that the social accounts direct consumers to your https://purerawz.co website to purchase your products. That is the same social-media-as-labeling reasoning that appears throughout this index.

The five cited products are tianeptine preparations. FDA separately notes that tianeptine is used as a prescription drug in some European, Asian, and Latin American countries but is not an FDA-approved drug in the U.S., and that the agency is aware of several serious adverse event reports associated with tianeptine and that consumers may find themselves addicted to tianeptine. A footnote points to FDA's own consumer update on the substance.

The evidence FDA quotes is the pattern this index has documented since 2023: statements from the firm's own product pages that name conditions and assert effects on them. One quoted line is worth reading closely, because it is written in the research register, not the promotional one — Tianeptine is a compound used primarily in research as a method to treat major depressive disorder[]. The bracketed insertion is FDA's: it marks where the agency trimmed the sentence. Research framing plus a named condition plus an asserted effect was still enough.

The remaining quoted claims are more conventional and considerably more explicit: several name psychiatric and respiratory conditions directly and assert effectiveness against them. They are described here instead of reproduced. This index does not reprint therapeutic claim copy at length even when a federal document is the source, and nothing in the evidentiary point requires it. The letter is linked in full below and the quotations are all in it.

Customer reviews, again, as intended-use evidence

The letter adds a separate evidentiary category, and states it in general terms first: Additionally, your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the treatment of disease and/or to affect the structure or function of the body. FDA then quotes five of them, each labeled with the product page's Reviews section it came from.

Two features are worth noting for anyone maintaining a store. First, the reviews are customer-written — the firm did not compose them, and the letter does not suggest it did. They counted as evidence because they were published on the firm's own pages. Second, FDA quoted them alongside the seller's own copy without distinguishing between the two: in the agency's reading, the page is the page.

One of the five quoted reviews describes a quantity taken and a time to effect. It is deliberately not reproduced here, and neither is any other administration detail from this or any letter in the index. That exclusion is a standing rule of this index and is noted so its absence is not mistaken for the document's silence.

This category has now appeared often enough to be a pattern — see reposted customer reviews as intended-use evidence.

A thirteenth disclaimer phrasing, disposed of the same way

PureRawz carried a human-use disclaimer. The letter handles it in the same single sentence the agency has used for years: Despite statements on your product labeling marketing your products as being for laboratory and research use only, the agency states, evidence obtained from your websites establish that your products are intended to be drugs for human use.

The wording of the disclaimer is new to this index. Earlier records had collected twelve phrasings, drawn from eleven primary documents — variations on research use, research purposes, laboratory use, analytical use, and not for human, animal or veterinary consumption. The phrase for laboratory and research use only is a thirteenth, bringing the record to thirteen distinct phrasings drawn from twelve primary documents spanning 2023 to 2026, counted as of September 6, 2026. The agency's answer did not change. As with every other letter in this index, the response does not analyze the disclaimer's wording at all; it simply states that the rest of the record outweighs it. Full record: the research-use-only disclaimer in the enforcement record.

The index says misbranded. The letter does not charge it.

FDA's searchable warning-letter index lists this letter under the subject Unapproved New Drugs/Misbranded. The letter charges unapproved new drugs, under sections 505(a) and 301(d). It contains no misbranding count, no reference to section 502, and no adequate directions for use allegation. The words misbrand and misbranded do not appear in the letter at all.

This is not a one-off. The same mismatch was recorded across all five letters in the August 24, 2026 batch — five index rows reading the same way, none of the five letters charging misbranding. With this letter it is six for six. The practical consequence is small but real: the index subject line is a routing label, not a statement of the counts charged, and anyone characterizing a letter from the index row alone will describe it wrongly.

The part that is genuinely unusual: FDA's scientists had already cited this site

In a briefing document prepared for the Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026, FDA evaluated TB-500 as a candidate bulk drug substance. Part of that evaluation surveys how the substance is sold online. Two of its footnotes list vendor product pages by full URL, and purerawz.co/product/tb-500/ is among them, accessed February 15, 2024.

The body sentence those URLs support is a plain marketing observation: several websites were found offering TB-500 in a range of powder sizes, and — in FDA's words — the websites state that the products are intended for research use only. The reviewers recorded the disclaimer without comment. They were answering a scientific question about a compound, not a compliance question about a seller.

The dates are what make this worth recording. The URL was accessed in February 2024. The warning letter issued in September 2025. The evaluation itself is dated May 15, 2026 and was published for the July 2026 meeting. So the document was written roughly twenty-seven months after the site visit it cites, eight months after the agency had written to that vendor — and it says nothing about the letter.

Nor are these distant corners of the agency. The evaluation's named authors include two officers of the Office of Compounding Quality and Compliance within CDER's Office of Compliance. The warning letter is signed by the Director of the Office of Unapproved Drugs and Labeling Compliance, within CDER's Office of Compliance. Two units of one office, looking at one website, eighteen months apart, for entirely different purposes.

Two vendors, the same result — the letter is never about the surveyed compound

PureRawz is not the only vendor to appear in both records. The December 2024 briefing document on CJC-1295 cites primepeptides.co/products/buy-cjc-1295 at footnote 71, accessed August 1, 2024, supporting an almost identical sentence: several websites sell CJC-1295 products, and the products are listed for research use only. Four months later, on December 10, 2024, FDA sent that firm warning letter 695156.

That letter does not mention CJC-1295. It cites two GLP-1-class products, on different product pages of the same domain. The string CJC-1295 appears in it zero times.

Two for two, the warning letter concerned something other than the compound the scientific evaluation had surveyed the vendor for. In the PureRawz case it concerned a different product category altogether.

This is a useful result mainly because of the reading it rules out. A table pairing "cited in an FDA briefing document" with "later received a warning letter" invites the inference that the first caused the second — that appearing in a footnote put a target on the vendor. On the only two cases available, that inference does not survive contact with the documents. The compliance actions ran on their own evidence, from their own website reviews, on their own timing, about products the scientific reviewers were not looking at.

What does the evidence not show?

1. It does not show FDA had no concerns about the peptide line. This is the most important limit on this page, and it cuts against everything above. The letter states expressly that it is not intended to be an all-inclusive statement of violations that may exist in connection with your products. The absence of a peptide count is not a finding that the peptides were compliant. It is the absence of a count.
2. Two cases are two cases. These are the only two vendors known to this index to appear in both an FDA scientific evaluation and an FDA warning letter. A consistent result across two instances is a reason to stop asserting the opposite; it is not a rule, and a third case could break it.
3. The currency gap is disclosed, not concealed. FDA date-stamps every one of these footnotes with the date the page was accessed. A reader can see exactly how old the survey is. Nothing here suggests the reviewers hid anything; the observation is only that a document published in 2026 rests on a 2024 snapshot of a market that moves faster than that.
4. A warning letter is not an adjudication. It states the agency's position and offers the recipient a chance to respond. No allegation in it has been tested in court.
5. Silence in the index row means nothing either way. FDA's row for this letter shows no response letter and no close-out letter. FDA's own guidance notes that matters described in warning letters may have been subject to later interaction that changed their regulatory status. An empty column is not evidence of an unresolved matter, or of a resolved one.
6. Neither vendor's current website was examined for this record. Everything here comes from four federal documents. What either site sells today, and whether either firm responded to its letter, is outside what these documents can establish and is not asserted.
7. Being cited in a briefing document is not a finding about a vendor. The footnotes establish that FDA reviewers observed a product being offered somewhere. They carry no assessment of the seller, the product, or its quality, and should not be read as one in either direction.

How to read this record

The narrow, checkable fact is that FDA does two different things with the same sentence. When its scientists survey a market, they record that sellers describe products as research-use-only, and move on — the disclaimer is a fact about the market. When its compliance office reviews one of those same sellers, the identical statement is set aside in a single sentence as insufficient against the rest of the site.

Both are consistent, because they answer different questions. The evaluation asks what a substance is and how it is being sold. The letter asks whether a particular seller's whole public record shows an intent that its products be used as drugs. A disclaimer is a truthful answer to the first question and, on this record, never a sufficient answer to the second.

For anyone reading these documents, the practical point is to keep the two apart. An FDA briefing document is not an enforcement signal, an FDA footnote is not an accusation, and an index subject line is not a list of counts. Each of the four documents behind this page says something precise, and none of them says what the pairing of them appears to suggest.

Sources

1. US FDA — Warning Letter, PureRawz, reference number 715218, September 8, 2025. fda.gov/…/purerawz-715218-09082025 — all quotations attributed to this letter are taken from this document.
2. US FDA — Warning Letter, Prime Vitality, Inc. dba Prime Peptides, reference number 695156, December 10, 2024. fda.gov/…/prime-vitality-inc-dba-prime-peptides-695156-12102024
3. US FDA — FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026; FDA Evaluation of TB-500-Related Bulk Drug Substances, dated May 15, 2026 (vendor-survey footnotes 36 and 41). fda.gov/media/193349/download
4. US FDA — FDA Evaluation of CJC-1295, briefing document for the Pharmacy Compounding Advisory Committee meeting of December 3–4, 2024 (vendor-survey footnote 71). fda.gov/media/183819/download
5. US FDA — Warning Letters index (searchable); the subject-line field quoted above is from this index, not from the letter. fda.gov/…/warning-letters
6. US FDA — Tianeptine Products Linked to Serious Harm, Overdoses, Death (consumer update cited in the letter's footnote 1). fda.gov/consumers/consumer-updates/tianeptine-products-linked-serious-harm-overdoses-death

Further reading

1. Prime Peptides warning letter record — the other vendor in the table above.
2. What the July 2026 FDA peptide vote did — and what it did not do — the meeting the TB-500 evaluation was written for.
3. What the 2024 FDA peptide votes decided — the meeting the CJC-1295 evaluation was written for.
4. The research-use-only disclaimer in the enforcement record — the twelve earlier phrasings.
5. Reposted customer reviews as intended-use evidence.
6. What an FDA warning letter is — and is not.
7. The 2024–2026 enforcement timeline.
8. Full vendor index — every entity record.

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.